⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 16, 2024

Supplementary Fig. 1 from Disruption of the MYC Super-Enhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

View Full Paper

Ask AI

Bookmark

Share

Abstract

Drug synergy between FLT3 and LSD1 inhibitors in FLT3-ITD and FLT3-wildtype cell lines.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yashar et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587522c5f https://doi.org/10.1158/1541-7786.27034651.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Fig. 1 from Disruption of the MYC Super-Enhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia2024
2Supplementary Fig. 8 from Disruption of the MYC Super-Enhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia2024
3Supplementary Fig. 8 from Disruption of the MYC Super-Enhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia2024
4Supplementary Fig. 3 from Disruption of the MYC Super-Enhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia2024
5Supplementary Fig. 3 from Disruption of the MYC Super-Enhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia2024